CHEST Guidelines-Clinical-Issues-in-Severe-Asthma

Clinical-Issues-in-Severe-Asthma_chest

Pdf Summary

The document is about a Continuing Medical Education (CME) program focused on the issues related to severe asthma, affecting over 300 million people worldwide. It emphasizes the disproportionate morbidity, mortality, and healthcare costs associated with severe asthma, which affects 5% to 15% of asthma patients. The program is geared towards healthcare providers like allergists, immunologists, and pulmonologists, aiming to enhance their understanding and treatment of diverse severe asthma phenotypes.<br /><br />The activity discusses critical topics regarding the classification of severe asthma, potential disease phenotypes, available biomarkers, and various biologic therapies targeting asthma's pathophysiology. The goal is to provide clinicians with the latest evidence and perspectives to aid in the personalized management of severe asthma.<br /><br />The CME program is led by a panel of experts who will explore how to differentially diagnose patients whose asthma remains uncontrolled despite intensive therapy, how particular biomarkers can guide therapy selection, and the effectiveness, mechanisms, and safety of biologic treatments. It is designed to help clinicians tailor therapeutic plans based on individual patient phenotypes and ongoing evaluation of symptoms, exacerbation risks, and comorbid conditions.<br /><br />The program provides an opportunity for physicians to earn CME credits, with the accreditation provided by the Accreditation Council for Continuing Medical Education (ACCME), and is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. The faculties involved in this educational activity have disclosed potential conflicts of interest with various pharmaceutical companies, partaking as consultants, advisors, or recipients of grant support, highlighting the importance of transparency in educational content development.

Keywords

severe asthma

CME program

healthcare providers

biologic therapies

asthma phenotypes

biomarkers

personalized management

continuing education

ACCME accreditation

Sanofi Genzyme